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Abstract
Preeclampsia (PE) is a disorder that occurs during pregnancy, it has an estimated world-
wide prevalence of 5–8%, being one of the leading causes of maternal and perinatal 
morbidity and mortality. Currently, different diagnostic criteria exist, however, due to 
its complexity; the clinical presentation that makes up this syndrome could make its 
presence unclear. The pathophysiology of PE has been recently postulated and divided 
into three processes: inadequate uterine remodeling, placental dysfunction and mater-
nal endothelial dysfunction. Despite the advances in the treatment of PE, the outcome 
of the medical interventions has failed to decrease the morbidity and mortality of this 
disease. The main reason might be the multifactorial origin of pathogenic processes that 
lead to the development of PE. That is why treatment is focused on the prevention of 
PE in patients that might present the risk before developing it late in pregnancy. The 
knowledge of the pathophysiological factors that trigger the processes that culminate in 
the presentation of PE, is key for prevention of this disease. However, the origin of these 
processes is poorly understood. It may be attributed to the ethical considerations that 
come with the study of these population of patients compared with the study of non-
pregnant women.
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1. Introduction
Preeclampsia (PE) is defined as a dysfunction in pregnancy, with a prevalence of 5–8% asso-
ciated with multiple complications and high rates of mortality around the globe. Around 
the world about 50,000–60,000 deaths contributing to PE occur annually, which describes its 
impact in maternal and fetal mortality globally. Hypertension is the main characteristic of this 
disease, with a blood pressure ≥140/90 mmHg assessed two occasions with a 4-h time laps in 
between one another. The presence of proteinuria (≥0.3 g/24 h or positive dipstick proteinuria) 
after the 20th week of gestation or the appearance of thrombocytopenia in absence of protein-
uria may also work as a diagnostic criterion [1, 2].
The risk of complications in the mother increases as a consequence of endothelial dysfunction. 
The risk of multiple cardiovascular diseases may increase in the fetus as well as in the mother 
later in life [2].
PE is a multisystem disease, a particular human syndrome that is specific to pregnancy. 
There are multiple factors present in the pathogenesis of preeclampsia, which go from 
genetic to environmental, but there is not a clear correlation between these factors and the 
development of PE. The scarce investigation in humans is due to legal and ethical limita-
tions. Multiple animal models have been tested to explain the pathophysiology and char-
acteristics of these diseases. Although there have been a great contribution, none have 
been able to completely reproduce all the events present in the human disease, such as the 
impaired trophoblast invasion and the disappearance of clinical findings once the placenta 
is removed. Still animal models have given us the biggest contributions to the understand-
ing of the etiology of the disease and have allowed us to test the effectiveness of multiple 
pharmacological interventions.
The actual recommendations for protecting the life of the mother are the interruption of preg-
nancy. The appropriate time for interruption of pregnancy is subject of further investigation 
to facilitate decision making. Gestational age of the fetus should take into account while mak-
ing decision without increasing the risk for the mother to develop severe complications that 
could lead to a maternal death. Despite all of these, the available medication for preventing 
or curing PE is not completely effective. For this reason, the objectives of this chapter are rec-
ommendations on the management of PE as well as new findings of the pathogenesis of the 
disease. Also, to establish rules and different genetic biomarkers to improve the identification 
of high risk patients and potential therapeutic targets that should be the focus of our atten-
tion in the coming years to prevent or manage adequate PE and avoid the consequences that 
involve one maternal death.
2. What is preeclampsia?
Preeclampsia is a disease defined as the presence of hypertension after the 20th week of 
gestation, accompanied by new onset proteinuria or by signs and symptoms regarding 
organ damage, these may include visual disturbances, headaches, epigastric pain and/or 
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rapid development edema. All of these manifestations are a result of the inadequate tro-
phoblastic invasion that occurs during the second half of pregnancy and results in endo-
thelial dysfunction [1, 2].
2.1. Diagnostic criteria PE
Many of the signs and symptoms that involve this syndrome might not become clearly evi-
dent, due to the complexity of PE, despite the systemic damage caused by endothelial dys-
function. The most notorious of these manifestations is the elevation of the blood pressure. The 
diagnostic criteria have evolved over time in order to achieve a specific and timely diagnosis.
Diagnosis includes the development of hypertension after 20 weeks of gestation in a 
woman with previous normal blood pressure. Hypertension is not the only criteria for 
diagnosing PE, in some cases other criteria such as proteinuria of new onset could be 
associated, or, in the case of absence of proteinuria, the diagnostic can be established with 
thrombocytopenia of new onset, pulmonary edema or visual or neurological disorders 
among others (Table 1) [1, 2].
2.2. Classification PE
PE is classified as:
• Mild: presence of hypertension with sustained SBP values: 140–159 mmHg or DBP 
 90–109 mmHg, proteinuria or one of the warning signs presented in Table 1.
• Severe: presence of SBP > 160 mmHg or DBP > 110 mmHg, proteinuria or one of the com-
plications presented in Table 1.
There are several guides with different diagnostic criteria and all them coincide that the evi-
dence of target organ damage can substitute the proteinuria accompanied to hypertension.
2.3. Current treatment of PE
The first consideration in the management of PE must be maintaining the safety of the mother 
and fetus. The second consideration has to be a delivery of a mature newborn that does not 
require prolonged intensive care (Table 3) [1, 2].
Once PE is diagnosed, subsequent management will depend on: the results of maternal and 
fetal assessment, gestational age, presence of labor or premature rupture of the membranes, 
vaginal bleeding and the mother wishes to extend the pregnancy.
An expectant treatment, without pharmacological intervention is frequently carried on, 
in the medical practice, in woman with mild PE that have a blood pressure that does not 
exceed SBP <160 mmHg and DBP <110 mmHg, and without complications. Nevertheless, 
this practice has been declining because new data indicates a greater benefit with the use of 
drug therapy. However, antihypertensive treatment is limited to methyldopa, labetalol and 
nifedipine, these interventions reduce high hypertension, but do not diminish the progres-
sion of PE [2].
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For women with severe PE presented before fetal viability, after interruption of pregnancy 
maternal stabilization is recommended. This must be done in an intensive care unit and com-
bine the use of labetalol, hydralazine and even nitroglycerin or sodium nitroprusside in addi-
tion to the drugs mentioned in previous lines [2] (Table 3). The use of magnesium sulfate 
deserves a special mention as it is used primarily to prevent eclampsia and not to promote 
a hypotensive effect. However, when used in combination with antihypertensive therapy, it 
reduces morbidity in patients with critical elevation in blood pressure [3].
Monitoring is essential to prevent serious complications of PE and it should be continued 
even after the establishment of treatment. Complications are divided into maternal and fetal 
(Table 2) [2].
Blood pressure 1. *SBP ≥ 140 or **DBP ≥ 90 mmHg on two occasions within 4 h after 20 WG in a woman 
with previous normal blood pressure.
2. If SBP ≥ 160 or DBP ≥ 110 mmHg, hypertension can be confirmed in a short time 
interval (minutes) to facilitate the initiation of antihypertensive therapy.
Plus
Proteinuria • ≥ 300 mg in 24 h urine (can be extrapolated to the time of collection).
• Ratio protein/creatinine ≥ 0.3 mg/dL.
• Dipstick reading of (≥ 1+) used only if there are no other quantitative method.
Or in the absence of proteinuria and or hypertension, with new onset of any of the following:
Central nervous system 1. Headache/visual disturbances.
2. Eclampsia. Reversible posterior leukoencephalopathy syndrome. Cortical blindness or 
retinal detachment. Glasgow < 13. Stroke. Transient ischemic attack. Reversible ischemic 
neurological deficit.
Cardiorespiratory system 1. Chest pain. Sat O2 < 97%.
2. Severe uncontrolled hypertension over a period of 12 hours despite the use of 3 
antihypertensive drugs. Oxygen saturation < 90%. Intubation, Pulmonary edema. The 
need of inotrope therapy.
Hematology 1. Leukocytosis. Elevation of ***INR or Prothrombin time. Thrombocytopenia.
2. Platelet count less than 100,000/microliter. Blood transfusion requirement.
Kidney 1. Elevation of serum creatinine and/or serum uric acid.
2. Acute kidney injury. Requirement for dialysis.
Hepatic 1. Nausea. Threw up. Epigastric pain right upper quadrant pain. Elevated liver 
enzymes, bilirubin or lactate dehydrogenase. Hypoalbuminemia.
2. Liver failure. Bruising or hepatic rupture
Feto-placental unit 1. Abnormal Fetal Hearth Rate. Oligohydramnios.
2. Abruption placentae with fetal and maternal morbidity. Fetal death.
1. Warning signs; 2. Complications
*(SBP) systolic blood pressure
**(DBP) diastolic blood pressure.
***(INR) International normalized ratio
Table 1. Diagnostic criteria for PE.
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Despite efforts to treat PE, treatment is symptomatic and focused on controlling blood pressure, 
so the recommendation remains in the completion of the deed at the right time. As for the time 
of delivery, it is preferred to prolong gestational age as long as possible, however, in severe PE; 
antihypertensive treatment and termination of pregnancy are recommended, if it is greater than 
34 weeks. If the pregnancy is less than 34 weeks and both mother and the product are stable it is 
recommended to continue the pregnancy and the administration of corticosteroids (Table 3) [1].
Currently, there are multiple criteria for better management of PE, but the only cure is the 
interruption of pregnancy, in which many times is a difficult decision for both the physician 
and the mother, due to the psychological burden, social, economic morbidity and mortality.
2.4. Clinical trials in PE
Despite advances in the treatment of PE and decades of research, the results of medical 
interventions have failed to significantly decrease the morbidity and mortality of this dis-
ease. The main reason seems to be the multifactorial causes of the pathogenic processes 
Mild PE Severe PE
Antihypertensive treatment*
24–<35 WG
Corticosteroids 48 h before termination of 
complicated pregnancy
Corticosteroids 48 h and immediate termination of pregnancy 
after maternal stabilization
≥35 WG
Should be immediate termination of pregnancy Immediate termination of pregnancy
WG, weeks of gestation.
*Methyldopa, labetalol, nifedipine, hydralazine.
Table 3. Treatment of PE.
Maternal Fetal
• Eclampsia
• Reversible posterior leukoencephalopathy syndrome
• Cortical blindness
• Retinal detachment
• Transient ischemic attack
• Severe hypertension
• Pulmonary edema
• Myocardial infarction
• Thrombocytopenia
• Acute renal damage
• Liver dysfunction
• Abrupt placenta
• Maternal death
• Prematurity
• Low birth weight
• Intrauterine growth restriction
• Delivery of a death product
Table 2. Complications of PE.
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that lead to the development of PE. Its inception happens late in pregnancy that is why the 
approach to manage these patients must be prevention. Knowing the factors that trigger 
the pathophysiological mechanism that lead to PE, is essential for its prevention. However, 
the etiology is still unknown and research in these patients is complicated due to the ethi-
cal considerations that must be taken into account. The multifactorial origin and the diffi-
culty of carrying out studies in the early stages of pregnancy can endanger for both mother 
and fetus [4].
There are currently 236,008 clinical trials registered in clinicalTrials.gov, of which only 3% 
are focused on pregnancy and of the latter 6.4% is about PE. Of all clinical trials dedicated 
to PE, 47.9% focus on strategies to improve treatment, 22.2% of the clinical trials aim to 
improve the diagnosis or its establishment in the early stages and 16.7% aims to establish 
the utility of new biomarkers, for both diagnostic and monitoring. Finally, only 10.7% of 
the clinical trials registered until February 1, 2017, are focused on the prevention of PE 
(Figure 1).
Another aspect that should be taken under consideration is that more than half of the clinical 
trials directed to PE are carried out in regions classified as first world, such as Europe and 
North America, whereas research in the rest of the world only constitutes 40%, despite the fact 
that developing countries are the ones that bear the greatest burden of morbidity and mortal-
ity caused by this disease (Figure 2).
Figure 1. Clinical trials registered until February 1, 2017. Data from: clinicaltrails.gov.
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2.5. Strategies in the prevention of PE
The understanding of the development of the placenta in patients with high risk pregnancy is 
essential to comprehend the pathophysiology for developing strategies of prevention.
Traditionally, the pathophysiological process has been divided into three stages.
2.5.1. Inadequate uterine remodeling
The invasion by the villi of the cytotrophoblasts in the decidual arteries and the myometrium 
arteries decreases to 56% and 76–18%, respectively. Neither endothelial cells nor smooth mus-
cle cells are replaced by trophoblasts, therefore they are not affected. Thus, the uterine arter-
ies, which have a smaller diameter, retain their vasoconstrictor potential which is the source 
of placental hypoxia, maladaptation of blood flow, as well as the phenomenon of ischemia—
reperfusion of the uterus and placenta [4, 5].
Inadequate trophoblastic invasion produces an imbalance between angiogenic factors, 
such as the vascular endothelial growth factor (VEGF), placental growth factor (PIGF) and 
anti-angiogenic factors as soluble fms-like tyrosine kinase 1 (sFlt-1 or sVEGFR1), a splice 
variant of the VEGF-receptor. During the first 10 weeks of gestation, sFlt-1 is elevated, 
even more in pregnant women with PE than in those healthy, with a second peak between 
26 and 29 weeks.
In preeclamptic pregnancies, sFlt-1 is produced excessively by the placenta much earlier 
than in healthy pregnancies and secreted into the maternal blood stream, where it is thought 
to bind and neutralize VEGF, and the VEGF subfamily member; PlGF with high affinity. 
This causes a decrease of VEGF and PlGF in maternal blood, and VEGF-signaling in the 
endothelial cells is disrupted as less VEGF receptors are bound. However, it is still unclear 
Figure 2. Clinical trials on PE reported by region. Reference: Clinicaltrials.gov.
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what causes the excessive sFlt-1 production and release. It could be shown that hypoxias, as 
well as the placental mass are triggers, but there may be others. The consequence of blocking 
VEFG and PIGF is a poor formation of the vascular bed of the placenta [6].
Another event that occurs early in the onset of symptoms, is the elevation of certain inflam-
matory cytokines such as alpha tumor necrosis factor (TNF-α) and interleukins IL-2, IL-4, 
IL-6, IL-8, IL-10, IL-12 and IL-8; these may initially lessen compared to healthy pregnant 
women. As the disease progresses over time, such cytokines showed an elevation in plasma 
levels. The activation of macrophages and natural killer cells leads to lysis of the trophoblast 
decidua cells [6].
Women that have a predisposition to develop PE, prior to the trophoblast invasion a general-
ized breakdown of the spiral arteries occurs, causing changes in preexisting vascular bed [4].
2.5.2. Placental dysfunction
At the beginning of the pregnancy, a state of hypoxia is presented, however, at the 10th week 
an increase of oxygen by the spiral arteries to overcome this state. In PE, placental dysfunction 
results from an inadequate placental trophoblast invasion which results in a release of pla-
cental products into maternal circulation. Placental dysfunction causes a prolonged state of 
hypoxia throughout the whole pregnancy resulting in high levels of hypoxia-induced factor-1 
(HIF-1α) during gestation. The prolonged state of hypoxia causes an oxidative damage to the 
placental barrier which increases fetal hemoglobin gene expression and free fetal hemoglobin 
accumulation in placenta. The accumulation of fetal hemoglobin and its metabolites due to is 
toxicity results in damage through three pathways [4, 7].
• 1st pathway: ferrous hemoglobin (Fe2+) binds to nitric oxide (NO), a potent vasodilator, and 
reduces the availability inducing vasoconstriction.
• 2nd pathway: Fe2+ hemoglobin is oxidized and reactive oxygen species (ROS) are released, 
provoking endothelial damage.
• 3rd pathway: the heme group of the hemoglobin molecule triggers an inflammatory 
response by activating neutrophils and cytokines production [4, 7].
The phenomenon of reoxygenation hypoxia generates oxidative stress, which induces placen-
tal dysfunction. Many cellular stress situations, such as an alteration in the redox state alters 
the maturation of proteins, leading to the accumulation of misfolded proteins in the lumen 
of the endoplasmic reticulum (ER), thereby producing a condition called “endoplasmic 
reticulum stress”, which triggers an adaptive response, called “unfolded protein response”, 
which aims to reduce the decrease proteins. In PE, the phenotype of placenta and intrauterine 
growth restriction are correlated with ER stress. In urine, misfolded proteins can be found, 
making it a viable biomarker for the Congo red test [7, 8].
The mother mounts an immune response against fetal trophoblast, which is detected as an 
alloantigen. PE could be consequential to a secondary inflammatory response derived from 
microparticles of microvilli of the syncytiotrophoblast (STMBs). The uterus-fetal perfusion 
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begins close to the end of the first trimester, and during the second and third trimester high 
levels of STMBs are detected in maternal circulation. The release of STMBs is affected by 
oxidative stress, which increases its release to maternal circulation creating an inflammatory 
response [4, 6].
Reactive oxygen species (ROS), like nitric oxide (NO), superoxide (O−2), hydrogen peroxide (H2O2), hydroxyl radical (OH) and peroxynitrite (ONOO−) are present all the time. Oxidative 
stress from unbalanced free radical formation is produced within the trophoblast cell, the 
sources may vary from O, eNOS uncoupling, NADPH oxidase and mitochondria. Proxynitrite 
formation, lipid peroxidation, protein modification, matrix metalloproteinase (MMP) activa-
tion and DNA damage contribute to endothelial dysfunction and are a result of the combina-
tion of these events [7, 9].
The main catalysts of O−2 are the antioxidant enzyme, superoxide dismutase (SOD) that converts it to H2O2 and water. H2O2 is immediately neutralized by the enzyme, catalase 
(CAT). PE is one of several conditions that after the ischemia-reperfusion, produces O−2 and by converting xanthine dehydrogenase (XD) to xanthine oxidase (XO) causes oxidative 
damage. Additionally, ATP metabolism in ischemic tissues forms hypoxanthine (HX) as a 
breakdown product. Xanthine and HX are converted into uric acid by XO, which also does 
the conversion of oxygen to O−2 and H2O2. In PE, superoxide generation by XO has been shown in placental reperfusion injury. Since PE is characterized by hyperuricemia, XO is 
presumably the source of uncontrolled ROS production when the concentration of its oxi-
dase form is increased [7, 9].
Another source of O−2 formation is NADPH oxidases. NADPH oxidase is a membrane-bound enzyme complex that catalyzes a one-electron reduction of oxygen and its transference to 
form O−2. It has been demonstrated that NADPH oxidase isoform, NOX1, is overexpressed in syncytiotrophoblast of preeclamptic placentas [7, 9].
3-nitrotyrosine residues have been observed in normal and complicated pregnancies, pre-
dominantly, in endothelium, surrounding smooth muscle and villous stroma. One of the 
key targets of ONOO− in PE is p38 mitogen-activated protein kinase (p38 MAPK), that has 
appeared significantly nitrated in placentas from preeclamptic women compared to nor-
motensive controls. Activation of the p38 MAPK pathway plays an important role in the 
release of pro-inflammatory cytokines and the induction of enzymes such as COX-2 which 
controls connective tissue remodeling in pathological conditions. Inducible nitric oxide syn-
thase (iNOS) expression, induction of VCAM-1 and, other adherent proteins along with other 
inflammatory-related molecules, and the effect of nitration of p38 MAPK in PE is currently 
under investigation for their use as molecular targets [7, 9].
But, not all free radicals cause disturbances in the organism and NO is an example. NO is 
a potent vasodilator, which acts on GTP to produce cGMP that causes relaxation of smooth 
muscle. It mediates endothelial function by regulating vascular tone, platelet aggregation, 
leukocyte adhesion and smooth muscle cells development. It is synthetized by the NOS fam-
ily of enzymes, which consist in three isoforms: nNOS or neuronal isoform, iNOS the induc-
ible and eNOS the endothelial NOS, formed from the reduction of l-arginine to l-citruline, 
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which is capable of dilating blood vessels. In placenta, eNOS expression is associated with 
cytotrophoblast to syncytotrophoblast differentiation [7, 9].
2.5.3. Maternal endothelial dysfunction
A reduction of vasodilating agents, such as NO and platelet PG2, a proliferation of vasopres-
sor agents and platelet aggregating agents, such as thromboxane A2 (TX A2) and endothe-
lin-1, alter the endothelial function. As a consequence of this imbalance, higher sensitivity 
combined with angiotensin II results in a state of vasoconstriction with an increased periph-
eral vascular resistance that creates an increase in blood pressure. Endothelial permeability is 
increased as well [10].
Regulation of the fetoplacental vascular reactivity, trophoblast invasion and apoptosis, and 
adhesion and aggregation of platelets in the intervillous space are all affected by NO, the 
main vasodilator in placenta. l-Arginine is the precursor of NO, which is formed in the pres-
ence of oxygen and tetrahydrobiopterin, a cofactor, resulting in the production of l-citrulline. 
When arginine residues in proteins are methylated by methyltransferases type I and II, they 
form asymmetric dimethylarginine (ADMA), a competitive inhibitor of l-arginine for the 
NOS isoform [11].
At the early stages of pregnancy, a hemodynamic adaptation as a response of an extra need 
for perfusion is induced by an increase in NO and a reduction in ADMA. As well, this 
adaptation permits uterine relaxation, which is necessary for intrauterine growth. Towards 
the end of pregnancy, the muscle fibers of the uterus suffer change, due to an increase in 
physiological ADMA, to undergo greater contractile activity and antagonize the effect of 
NO. In pregnancy with high risk of PE, ADMA levels increase to higher than normal, reason 
why many studies have suggested the possibility of using it as a biomarker of endothelial 
dysfunction [11, 12].
TXA2 works as a vasoconstrictor and in patients with high risk of PE, its levels increase all 
together with the circulating levels of TXB2, one of its metabolites. TXA2 is produced in 
platelets and endothelial cells and is one the many molecules derived from arachidonic acid 
through prostaglandin H synthase (PGHS). The TXA2 receptor (TP) mediates the constrictor 
effects of TXA2 in vascular smooth muscle.
The vasoconstrictive effects of TxA2 in PE are amplified because of their ability to potenti-
ate the vasoconstrictor effects of angiotensin II and endothelin-1. NO and I2 (PGI2) inhibit 
prostaglandin TxA2 actions through TP receptor desensitization; however, in pregnancies 
with PE, NO production and PGI2 are affected. Research profiles of DNA methylation of 
omental arteries reveal that the gene, thromboxane synthase (TBXAS1), is hypomethyl-
ated, even more significantly in the vessels of women with PE and this was associated 
with the increased expression of thromboxane synthase in the omental arteries women with 
PE. Taken together, these data suggest that, in PE, there is an imbalance in the production 
of vasoconstrictors (TxA2) and vasodilator prostanoids (PGI2), modulated by epigenetic 
modifications [13].
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It is also reported in the literature the presence of autoantibodies against angiotensin receptor 
1 (AT-1). These autoantibodies have a pharmacological effect similar to that of angiotensin 
II agonist. Stimulation of the AT-1 receptor by these circulating autoantibodies could also be 
responsible for hypertensive symptoms in PE, as the concentration of circulating autoantibod-
ies increases after 20 weeks of gestation [6, 14].
3. Identification of high risk patients
PEs pathogenic process begins during the first quarter, long before clinical signs are evident. 
Therefore, it is difficult to identify early biomarkers. Although there is no perfect way to pre-
dict the development of PE, it is possible to distinguish between women who have a high risk 
of developing PE of those whom have a low risk (Table 4).
However, these factors predict only 30% of women who develop PE. Biomarkers in maternal 
blood have a modest predictive potential. Prediction of early onset of PE at the end of the first 
quarter of pregnancy can be done using Doppler ultrasound combined with plasma levels of 
placental growth factor and protein-A associated with pregnancy (PAPP-A) [15].
4. The use of biomarkers for PE
An effective biomarker to predict of the onset of PE has not been established, some the most 
promising biomarkers are listed in Table 2. The heterogeneity of the pathogenesis of PE makes 
it difficult to establish a single biomarker as a predictor of the disease; the best approach 
might be a combination of markers. However, much research and development of criteria 
High risk factors Moderate risk factors
PE in previous pregnancies. Women who have PE in the 
first pregnancy have 7 times more risk of developing PE in a 
second pregnancy (RR 7.19; 5.85–8.83).
Hypertension in pregnancy. The prevalence of chronic 
hypertension in women who develop PE is 12% (RR 5.2; 
1.5–17.2).
Renal disease. The prevalence of renal disease in women who 
develop PE is 5.3%.
Diabetes mellitus 1 and 2. The probability of PE almost 
quadruples if diabetes is present before pregnancy (RR 3.56; 
2.54–4.99).
Autoimmune diseases. Women who develop PE are more 
likely to have an autoimmune disease (RR 6.9; 1.1–42.3). 
Antiphospholipid syndrome significantly increases the risk of 
developing PE (RR 9.72; 4.34–21.75).
Primigravid. Nulliparity almost triples the risk of 
PE (RR 2.91; 1.28–6.61).
Maternal age. The risk increases 30% for every 
completed year after 34.9. The risk increases twice 
in nulliparous ≥40 years (RR 1.68; 1.23–2.29).
Interval intergenesic >10 years. The risk of PE is 
about the same as that of nulliparous (RR 1.12; 
1.11–1.13).
Body mass index (BMI) ≥ 35 kg/m2. The risk of PE is 
increased up to 50% (RR 4.39; 3.52–5.49).
Family history of PE. This almost triples the risk of 
PE (RR 2.90; 1.70–4.93).
Multiple pregnancy. Twin pregnancy nearly triples 
the risk of PE (RR 2.93; 2.04–4.21), while a triplet 
pregnancy nearly triples the risk of twin pregnancy 
(RR 2.83; 1.25–6.40).
Table 4. The most important for the development of PE factors [15, 16].
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Biomarker Characteristics Studies
sFlt-1/PlGF It has been included sFlt-1/PlGF ratio 
into German PE guidelines for care. A 
ratio of sFlt-1/PlGF: 38 at any time during 
pregnancy is considered as suspected PE, 
while PE is considered diagnostic of figures 
85 and 110 before and after 34 weeks of 
gestation, respectively.
Stepan in 2015 shows that circulating levels 
of sFlt-1 are increased significantly more a 
month before the appearance of the first clinical 
symptoms detectable. In the case of PlGF, 
significantly lower concentrations are observed 
in women who subsequently present placental 
dysfunction since the end of the first quarter. 
They concluded that further studies are needed 
to demonstrate the benefits of using the ratio of 
sFlt-1/PlGF in terms of reduction of maternal 
and fetal risks and resource optimization [17].
Soluble endoglin 
(Seng)
A truncated form of the receptor for 
β1-transforming growth factor (TGF-β1) 
and TGF-β2 that interferes with the binding 
of TGF-β1 to its receptor, and thereby 
affects the production of nitric oxide, 
vasodilation and capillary formation by the 
endothelial cells in vitro.
Levine et al. showed in 2006, in a nested case 
study that circulating levels of soluble endoglin 
increased from 2 to 3 months before the clinical 
onset of PE controls. After the onset of the 
disease, the average level of serum in women 
with PE remains high until the end of pregnancy 
(31.0 ng/ml, as compared to 13.3 ng/ml in 
controls (p < 0.001) A higher level of soluble 
endoglin is usually accompanied by an increase 
in the proportion of sFlt1: PlGF [18].
PAPP-α A highly glycosylated protein that 
is produced by trophoblast cells in 
development has proven to be an insulin-
like growth factor. Therefore, as expected, 
low serum levels of PAPP-α are associated 
with a higher incidence of PE.
The studies are contradictory, while some 
show association with low levels of PAPP-α, 
others observed elevations in serum. Both 
observations were made by Bersinger et al. In 
two separate case-control study in 2003 and 
2004, respectively [19, 20].
Activin-A This is a glycoprotein member of the TGF-β 
family that is released by the placental-
fetus unit during pregnancy. Activin-A is 
involved in various biological activities [21].
A case-control study conducted in 2004 by Ong 
et al. found that levels of activin-A are higher 
PE than in normal pregnancies. It has been 
observed that an increase in activin-A occurs 
before 14 weeks of gestation in pregnancies 
with PE.
PP-13 A 32-kd dimer protein is one of 56 known 
placental proteins, produced exclusively 
by placenta and it facilitates trophoblast 
invasion and maternal artery remodeling 
[22]. A higher magnitude of increase of 
PP13 from the first to the third trimester 
was observed in PE [23].
Gonen et al., in 2008 conducted a study of cases 
and controls in pregnancy between  
5 and 7 weeks and determined the relation of 
lower values of PP-13 in PE than in normal 
pregnancies. The increase of PP-13 in maternal 
blood seems to coincide with STBM release as 
the PE advances.
Cystatin C A protease inhibitor is widely used by 
clinicians as a sensitive marker for renal 
function and for estimating glomerular 
filtration rate. Increased levels of cystatin-C 
may be attributed to an increased placental 
production.
Thilaganathan et al. in 2009 conducted a nested 
case study to determine levels of cystatin C, a 
marker set for kidney function, which increases 
progressively as the glomerular filtration rate 
falls. In PE, placental expression of cystatin C 
is significantly increased in the first trimester 
of pregnancy compared to those with normal 
pregnancy [24].
Fetal hemoglobin Oxidative damage induces placental 
production and leakage in the fetal-
maternal hemoglobin barrier.
Recent studies have identified it as a predictor 
in the first and second quarters [25].
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are needed. There is a need for biomarkers that could also apply to patients that apparently 
do not have any risk factors for developing PE, and research should expand its investigation 
regarding these patients (Table 5).
sFlt-1, soluble fms-like tyrosine kinase 1; PlGF, placental growth factor; ADMA, asymmetric 
dimethylarginine; PAPP α, pregnancy-associated plasma protein-A; PP-13, placental protein 
13; miRNA, microRNA; STMB, syncytiotrophoblast microvesicles.
5. Pharmacological approach for prevention
5.1. Calcium administration
According to an study conducted by Hofmeyr et al., supplementation of calcium in 
women that have a low calcium intake and mild risk of PE have a relative risk of 0.48 (95% 
CL 0.33–0.69). However, patients that have a low calcium intake and a high risk of PE 
displayed a major benefit (RR .22; 95% CL 0.12–0.42). Low levels of calcium increase vaso-
constriction resulting in high blood pressure, by liberating parathyroid hormone or releas-
ing renin, and consequently increasing intracellular calcium in vascular smooth muscle. 
Parathyroid hormone release and intracellular calcium levels are reduced with calcium 
administration [31].
Biomarker Characteristics Studies
ADMA and 
homocysteine
Serial measurements of their concentrations 
may be useful to identify women at risk 
[26].
López-Alarcón et al., in a cohort study in 2015 
found that ADMA and homocysteine (Hcy) 
increases gradually throughout pregnancy with 
PE, but remains constant in women without 
complications. ADMA and homocysteine 
increase 1 month prior to the onset of 
PE. Increases of up to 80 nmol of ADMA and 
Hcy 1000 nmol to 1, a month prior to the onset 
of PE. This has demonstrated the best potential 
for prediction
miRNA miR-16 is stimulated by hypoxia and 
inhibits migration of cytotrophoblast cells 
[27], it represses production of VEGF 
receptors in mesenchymal stem cells 
derived from the decidua (MSCs), and 
induces cell cycle arrest in the transition  
G0/G1 [28].
miRNA-155 overexpression reduces the 
expression of NOS [29].
C19MC miRNAs are downregulated 
exclusively associated with preeclampsia 
[30].
There are more angiomiRNAs that have been 
found and vary on their level of expression. 
However, there is still a lack of investigations to 
understand their role as biomarkers.
Table 5. Potential biomarkers in preeclampsia.
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5.2. Acetylsalicylic acid administration
The inhibition of thromboxane A2 formation without affecting the production of prostacy-
clins, gives acetylsalicylic acid in low doses an anti-platelet aggregating an anti-vasoconstrictor 
effect. This justifies its use in PE; however, the results have been controversial about the posi-
tive role of its administration at the onset of the pregnancy and the severity of its use.
Campos concluded, from a systemic review, that since there are no pharmacological alterna-
tives, physicians should administer low doses of aspirin from 60 to 150 mg per day starting in 
the first quarter through to week 16. Administration should be performed overnight because 
it helps in reducing the risk of PE [32].
5.3. NO pathway
Since endothelial dysfunction and impaired bioavailability of NO are taxpayers of maternal 
manifestations of PE, supplementation with exogenous NO donors would be an apparent 
solution.
Trapani et al. conducted a study in which nitroglycerin transdermal patches were applied into 
the mother’s abdomen to improve the uteroplacental circulation. They reported an increase of 
the blood flow in the uterine and umbilical arteries. However, further investigation is needed 
for their effect reducing the incidence of PE [33].
Groten et al. found that pentaerythritol tetranitrate, an organic nitrate of prolonged action, 
improves uteroplacental perfusion in women at risk of PE, as well as reducing its frequency, 
growth restriction and premature births it may cause in these women [34].
Moreover l-arginine acts as a precursor of NO and becomes NO and l-citrulline by NOS, as 
described in the pathophysiology of PE. It has been the subject of studies designed to investi-
gate its preventive role in women with high risk of developing PE.
Figure 3. The pathological processes and the clinical manifestations are listed chronologically, with the key moments for 
pharmacological intervention pointed out at every stage of the pregnancy.
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Camarena et al. published in 2016 a clinical trial which included 100 pregnant women at 
high risk for PE to estimate the effectiveness and safety of l-arginine for preventing PE. They 
formed two study groups, one was given 3 g of l-arginine per day in 600 mg capsules, and 
a second group was given placebo capsules approved with L-arginine. They found a lower 
incidence of PE in the group receiving l-arginine to the placebo (6 and 23%, respectively; 
p = 0.016) group, which was statistically significant, and also reported an increased incidence 
of severe PE in the placebo compared to the intervention group (14 and 2%, respectively, 
p = 0.02) group. SBP, DBP and MAP decreased significantly in the group treated with l-argi-
nine compared with the placebo (p = 0.022, p = 0.035 and p = 0.023, respectively). The most 
common adverse event was dyspepsia, which was higher in the intervention group than in 
the placebo (26 and 6%, respectively; p = 0.008) group. The authors concluded that adminis-
tration of l-arginine is effective and safe to prevent PE [35].
As seen in Figure 3, we can establish several moments as opportunities for prevention or 
management of PE, the best opportunity for treating PE is prior to pregnancy by identify-
ing women with high risk and creating strategies to prevent the development of the disease. 
During pregnancy, several potential targets could modify its course; we listed in a timeline 
the molecules that have an implication in the pathogenesis of PE.
6. Conclusions
PE is a serious complication of pregnancy, which has a high rate of morbidity and mortal-
ity worldwide. Due to the complexity of PE, and despite the systemic damage caused by 
endothelial dysfunction, many of the signs and symptoms that make up this syndrome may 
not be clearly evident, being the most notorious sign an elevation of the blood pressure. The 
diagnostic criteria have evolved over time in order to achieve a timely and specific diagnosis, 
but this has only caused a more complex evaluation, so it requires new tools to achieve an 
early and accurate diagnosis of the PE.
Antihypertensives are an alternative for the treatment of PE, however, they stretch the preg-
nancy until the product is viable to live outside the uterine environment, shortening gesta-
tion. The outcome using hypertensives is not always favorable for the mother and the fetus 
and their effect on PE is variable.
During the early stages of placentation, various changes may occur due to intrinsic factors, so 
this should be the focus of investigation. However, invasive procedures to pregnant women 
are not acceptable because of the risk they might represent without any notable benefit.
The combination of several biomarkers could contribute to identify women with mild and 
high risk of developing the disease, which is the best strategy for prevention and manage-
ment of PE.
In past years, a lack of therapeutic options regarding PE was notorious. However, new oppor-
tunities have surged in present years such as, inmunomodulators, antioxidants, angiom-
RNAs and nitric oxide donors, which are still under investigation but have shown promising 
results. Nevertheless, prevention persists as the principal strategy to reduce morbi-mortality 
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of PE. The obstetrician is responsible for evaluating the individual options each patients has, 
even before conception and research should focus on developing new and better strategies.
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